DexCom received a warning letter from the Food and Drug Administration following inspections of two of its plants.

Wells Fargo analyst Larry Biegelsen keeps an Overweight rating on DexCom (DXCM) with a $98 price target after the company disclosed that a ...

DexCom received a warning letter from the Food and Drug Administration ... noted "deficiencies in the response" from DexCom to the FDA's Form 483, which outlines observations from investigators.

DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising ...

The company does not expect the warning letter to materially impact its manufacturing capacity, sales or ability to seek ...

Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...

DexCom said that on Tuesday it received a warning letter from ... systems. The FDA cited issues with DexCom's response to prior inspection findings, known as Form 483 observations.

The warning ... from the letter to its manufacturing capacity or its sales guidance for fiscal year 2025. Advt Dexcom said it had already submitted responses to the so-called "Form 483" and ...